MSN Laboratories announced the launch of Posaconazole, a triazole antifungal agent indicated for treating Black Fungus (Mucormycosis) patients, in India.

According to a press release issued by the company, MSN has launched the product under the brand name PosaOne as 100 mg Delayed-Release tablets and 300 mg injections, respectively.

“As an outcome of MSN”s competence in research and manufacturing of anti-fungal infection drugs, it is now targeting to pro-actively reach patients across India by ensuring the access ofPosaOne, through its strong distribution network & field force,” the company said.

MSN has developed the active pharmaceutical ingredient and the formulation of PosaOne in its in-house Research and Development and manufacturing units.

The drug is approved by the Drug Controller General of India (DCGI).

As part of the COVID treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200 mg, 400 mg and 800 mg, OSELOW (Oseltamivir) as 75 mg capsules and also licensed Baridoz (Baricitinib) recently with Eli Lilly.